MARATTO

article · SVU-International Journal of Medical Sciences

Clomiphene Citrate versus Clomiphene Citrate in combination with other drugs in Ovulation Induction in Patients with Polycystic Ovary Syndrome

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most prevalent cause of normogonadotrophic anovulation, also classified as World Health Organization group II anovulation. Objectives: The aim of this study was to compare the effectiveness and clinical outcomes of clomiphene citrate alone and with different combinations (metformin , tamoxifen , letrozole and low dose gonadotrophins ) in induction of ovulation in women with PCOS. Patients and methods: The Obstetrics and Gynecology department at Qena University Hospital, South Valley University, was the site of this randomized study. The study included 400 infertile cases with PCOS divided on 5 groups . The duration of the study ranged from 12-24 months. Results: In the studied groups, group 4 (clomiphene and letrozole ) and group 5 (clomiphene and low dose gonadotrophins) had the highest ovulation rate which was 31.3 % , 41.3 % respectively and also the highest pregnancy rate which was 33.8 % for each group . Conclusion: The combination of clomiphene and letrozole and clomiphene and gonadotrophins had proved to be the most effective , low cost infertility treatment in women with PCOS that offers high ovulation and pregnancy rates.

Research topics

  • Ovarian function and disorders
  • Reproductive Biology and Fertility
  • Healthcare and Venom Research

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/svuijm.2023.194749.1534

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.